Tom Gyllenhammar1, Eva Fernlund2, Robert Jablonowski1, Jonas Jögi1, Henrik Engblom1, Petru Liuba2, Håkan Arheden1, Marcus Carlsson3. 1. Department of Clinical Physiology, Lund University, Lund University Hospital, Lund 221 85, Sweden. 2. Department of Pediatric Cardiology, Lund University, Lund University Hospital, Lund, Sweden. 3. Department of Clinical Physiology, Lund University, Lund University Hospital, Lund 221 85, Sweden marcus.carlsson@med.lu.se.
Abstract
AIMS: To determine if myocardial perfusion (MP) during hyperaemia is decreased in young patients with hypertrophic cardiomyopathy (HCM). Also, to determine if an MP decrease is associated with diastolic dysfunction, and to investigate if young subjects at risk of HCM show differences in MP compared with controls. METHODS AND RESULTS: This study included 10 HCM patients (age 22.3 ± 6.4 years), 14 subjects at risk for HCM 'HCM risk' (age 18.9 ± 3.8 years), and 12 controls (age 22.8 ± 4.5 years). HCM patients were examined at rest and during hyperaemia (adenosine 140 µg/kg/min) with cardiovascular magnetic resonance (CMR) and echocardiography. MP was calculated as the ratio of coronary sinus flow and left ventricular mass (LVM) from CMR. Myocardial fibrosis was assessed using late gadolinium enhancement. Diastolic function was quantified with both echocardiography and CMR. At rest, MP (mL/min/g) was similar in the control, HCM risk, and HCM patients (0.8 ± 0.1, 1.0 ± 0.1, and 0.9 ± 0.1, respectively, P = ns). During adenosine, MP was lower in HCM patients (2.5 ± 0.4, P < 0.05) compared with both HCM risk (5.0 ± 0.5) and controls (3.9 ± 0.3). Subjects at HCM risk showed no significant difference in MP during adenosine compared with controls. One HCM patient showed mild diastolic dysfunction. Neither controls nor HCM risk individuals showed any sign of myocardial fibrosis, whereas 7/10 HCM patients had fibrosis (5 ± 1% of the total LVM). CONCLUSION: Young individuals with HCM, but not those at risk, show decreased MP during hyperaemia compared with controls even in the absence of diastolic dysfunction or LV outflow obstruction. These results may suggest that microvascular disease contributes to the decreased MP in the investigated population. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: To determine if myocardial perfusion (MP) during hyperaemia is decreased in young patients with hypertrophic cardiomyopathy (HCM). Also, to determine if an MP decrease is associated with diastolic dysfunction, and to investigate if young subjects at risk of HCM show differences in MP compared with controls. METHODS AND RESULTS: This study included 10 HCM patients (age 22.3 ± 6.4 years), 14 subjects at risk for HCM 'HCM risk' (age 18.9 ± 3.8 years), and 12 controls (age 22.8 ± 4.5 years). HCM patients were examined at rest and during hyperaemia (adenosine 140 µg/kg/min) with cardiovascular magnetic resonance (CMR) and echocardiography. MP was calculated as the ratio of coronary sinus flow and left ventricular mass (LVM) from CMR. Myocardial fibrosis was assessed using late gadolinium enhancement. Diastolic function was quantified with both echocardiography and CMR. At rest, MP (mL/min/g) was similar in the control, HCM risk, and HCM patients (0.8 ± 0.1, 1.0 ± 0.1, and 0.9 ± 0.1, respectively, P = ns). During adenosine, MP was lower in HCM patients (2.5 ± 0.4, P < 0.05) compared with both HCM risk (5.0 ± 0.5) and controls (3.9 ± 0.3). Subjects at HCM risk showed no significant difference in MP during adenosine compared with controls. One HCM patient showed mild diastolic dysfunction. Neither controls nor HCM risk individuals showed any sign of myocardial fibrosis, whereas 7/10 HCM patients had fibrosis (5 ± 1% of the total LVM). CONCLUSION: Young individuals with HCM, but not those at risk, show decreased MP during hyperaemia compared with controls even in the absence of diastolic dysfunction or LV outflow obstruction. These results may suggest that microvascular disease contributes to the decreased MP in the investigated population. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Anna Wålinder Österberg; Ingegerd Östman-Smith; Robert Jablonowski; Marcus Carlsson; Henrik Green; Cecilia Gunnarsson; Petru Liuba; Eva Fernlund Journal: Pediatr Cardiol Date: 2021-01-30 Impact factor: 1.655
Authors: Robert Jablonowski; Eva Fernlund; Anthony H Aletras; Henrik Engblom; Einar Heiberg; Petru Liuba; Håkan Arheden; Marcus Carlsson Journal: Pediatr Cardiol Date: 2015-06-12 Impact factor: 1.655
Authors: E Fernlund; T Gyllenhammar; R Jablonowski; M Carlsson; A Larsson; J Ärnlöv; P Liuba Journal: Pediatr Cardiol Date: 2017-03-30 Impact factor: 1.655
Authors: Adam L Dorfman; Tal Geva; Margaret M Samyn; Gerald Greil; Rajesh Krishnamurthy; Daniel Messroghli; Pierluigi Festa; Aurelio Secinaro; Brian Soriano; Andrew Taylor; Michael D Taylor; René M Botnar; Wyman W Lai Journal: J Cardiovasc Magn Reson Date: 2022-07-21 Impact factor: 6.903
Authors: Tom Gyllenhammar; Mikael Kanski; Henrik Engblom; Dirk M Wuttge; Marcus Carlsson; Roger Hesselstrand; Håkan Arheden Journal: BMC Cardiovasc Disord Date: 2018-01-30 Impact factor: 2.298
Authors: Rebecca K Hughes; Claudia Camaioni; João B Augusto; Kristopher Knott; Ellie Quinn; Gabriella Captur; Andreas Seraphim; George Joy; Petros Syrris; Perry M Elliott; Saidi Mohiddin; Peter Kellman; Hui Xue; Luis R Lopes; James C Moon Journal: J Am Heart Assoc Date: 2021-07-27 Impact factor: 5.501